Clene's Participation in May 2024 Investor Conferences and Its Impact on Neurodegenerative Disease Treatment

What is Clene and what does it focus on?

Clene is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases such as ALS, MS, and Parkinson’s disease.

What is CNM-Au8(R) and how does it work?

CNM-Au8(R) is an oral suspension developed by Clene to restore neuronal health and function by increasing energy production and utilization in the treatment of neurodegenerative diseases.

Which investor conferences did Clene participate in during May 2024?

Clene participated in the Mizuho Neuroscience Summit 2024, the Benchmark 2024 Healthcare House Call Virtual Conference, and the Virtual A.G.P. Healthcare Conference.

What is the significance of Clene’s participation in these conferences?

These conferences provided Clene with the opportunity to present its lead drug candidate CNM-Au8(R) to investors and stakeholders, showcasing its potential in treating neurodegenerative diseases.

Has CNM-Au8(R) been tested in clinical trials?

Yes, CNM-Au8(R) has been involved in clinical trials and compassionate use programs, accumulating over 600 years of exposure across various neurodegenerative conditions with no safety concerns reported.

Where can I find more information about Clene and its developments?

More information about Clene and its developments can be found in the company’s newsroom at https://ibn.fm/CLNN or by visiting their corporate communications at www.InvestorBrandNetwork.com.

Who can I contact for more information about Clene?

For more information about Clene, you can contact IBN (InvestorBrandNetwork) at 310.299.1717 or via email at Editor@InvestorBrandNetwork.com.